Lincomycin
- Atc Codes:J01FF02
- CAS Codes:7179-49-9#859-18-7#154-21-2
- PHARMGKB ID:7179-49-9#859-18-7#154-21-2
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Belgium: Lincocin; Bulgaria: Lincomycin; Cyprus: Medoglycin; France: Lincocine; Greece: Lincocin, Lincomicina, Pecasolin; Italy: Cillimicina, Lincocin; Latvia: Lincocin; Lithuania: Lincocin; Poland: Lincocin, Lincomycin, Neloren; Portugal: Lincocina; Romania: Lincodar; Slovenia: Neloren; Spain: Cillimicina, Lincocin.
North America
Canada: Lincocin; USA: Lincocin.
Latin America
Argentina: Frademicina; Brazil: Farmicina, Frademicina, Linatron, Lincoflan, Lincomicina, Lincomiral, Lincovax, Lindemicina, Neo Linco; Mexico: Bactokina, Libiocid, Limidrax, Lincocin, Lincomicina, Lincopat, Lincover, Lisonin, Loriz, Princol, Rimsalin, Yectolin.
Asia
Japan: LCM, Lincocin, Lincomeis, Lintamycin, Lizpion, Luniamycin, Pelancocin.
Drug combinations
Lincomycin and Neomycin
Chemistry
Lincomycin Hydrochloride: C~18~H~34~N~2~O~6~S HCl H~2~O. Mw: 461.01. (1) D-erythro-α-D-galacto-Octopyranoside, methyl 6,8-dideoxy-6-[[(1-methyl-4-propyl-2-pyrrolidinyl)carbonyl]amino]-1-thio-, monohydrochloride, monohydrate, (2S-trans)-; (2) Methyl 6,8-dideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-D-erythro-α-D-galacto-octopyranoside monohydrochloride monohydrate. CAS-7179-49-9; CAS-859-18-7 (anhydrous); CAS-154-21-2 (lincomycin).
Pharmacologic Category
Miscellaneous Antibacterials; Lincomycins. Lincosamide Antibiotic. (ATC-Code: J01FF02).
Mechanism of action
Antibiotic isolated from a strain of Streptomyces lincolnensis. Inhibits bacterial protein synthesis by binding on 50S subunit, affecting process of peptide chain initiation. Only one molecule of antibiotic can bind to a single ribosome.
Therapeutic use
Treatment of serious susceptible bacterial infections, mainly those caused by Streptococci, Pneumococci, and Staphylococci resistant to other agents.
Pregnancy and lactiation implications
Unlabeled use
Contraindications
Hypersensitivity to lincomycin, clindamycin, or any component of the formulation.
Warnings and precautions
Can cause mild-to-severe (and possibly fatal) colitis. Prolonged use may result in fungal or bacterial superinfection, including C. difficile-associated diarrhea and pseudomembranous colitis. Hypersensitivity reactions including anaphylaxis and rarely, erythema multiforme (resembling Stevens-Johnson syndrome) reported. Use with caution in significant allergies, asthma, history of gastrointestinal disease (particularly colitis), hepatic or renal impairment, and in the elderly. Solution for injection contains benzyl alcohol (associated with «gasping syndrome» in neonates). Not appropriate for use in treatment of meningitis due to inadequate penetration into CSF.